Extended Data Fig. 3: Viral sensitivity to PGT121 and other bNAbs before and after PGT121 infusion. | Nature Medicine

Extended Data Fig. 3: Viral sensitivity to PGT121 and other bNAbs before and after PGT121 infusion.

From: Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

Extended Data Fig. 3

IC50 neutralization scores (in µg/ml) are shown for each participant: PGT121 is shown on the left, followed by 10–1074 that also targets the V3 glycan, then a V2 apex bNAb (PGDM1400), then a CD4bs bNAb (3BNC117). Baseline and post PGT121 treatment values are shown, followed by the amino acid sequence of the GDIR motif (HXB2 positions 324–327) and the N-linked glycosylation motif (positions 332–334). Blue amino acids indicate sensitivity signatures for PGT121, while black and red amino acids indicate resistance signatures.

Back to article page